NR4A2 and neoplasm: Subsequent deletion of IRF8 in NR4A2/hA1R engineered CAR T cells abrogated the enhanced cytokine production in both serial and long-term stimulation assays and suppressed A1R driven enhanced tumor killing during the second round of long-term restimulation.